The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
What is a great shame is the person who did find this information gets ridiculed by the idiot who has so after ridiculed that group but then goes on to pontificate about it’s importance
“whoever found it on Reddit. Twitter finds used to be pmjh'speciality. - sitting in his basement”
Thanks for the link Brysoa
Most intriguing that they sponsor a piece of work that they themselves have already done and presented on.
Why would you do that and why would UKHSA be interested unless there’s a conversation in the background #100DM
https://www.gov.uk/government/publications/100-days-mission-uk-specific-report-for-2022/100dm-how-the-uk-is-contributing-to-the-global-mission-to-develop-pandemic-fighting-tools-within-100-days
The key here is NOT who’s test is being used.
They’re presenting on pandemic preparedness and variant escape. Highlighting how monoclonals had been escaped and therapeutics remain limited.
They chose our drug to use as an example
Good question Brand
Seems it’s part of the newly created
The Vaccine Development Evaluation Centre (VDEC) at Porton Down in Wiltshire facilitates the development and evaluation of new vaccines and therapeutics.
I don’t think we’ve seen Synairgen independently tested and presented by a government body before. This appears to be instigated and chosen by this body as an example for pandemic preparedness and for its agnostic benefits. Most of the presentation team for this abstract are UKHSA
Great find
The final paragraph is quite interesting as are the people leading the presenting - Government agency UKHSA (Amanda Horton) and of course the compound they chose to present on
A368
The antiviral efficacy of interferon-β1a (SNG001) against different SARS-CoV-
2 variants, in vitro.
Amanda Horton1, Sarah Dudley2, Matthew Wand1, Daniel Packham1, Irene CanoCejas1, Victoria
Tear2, Phillip Monk2, Mark Sutton1, Julia Tree1
1UKHSA, Salisbury, United Kingdom. 2Synairgen Research Ltd., Southampton, United Kingdom
Abstract
With the emergence of SARS-CoV-2 variants resistant to monoclonal antibody therapies and limited
global access to therapeutics, the evaluation of novel therapeutics to prevent progression to severe
COVID-19 remains a critical need. Inhaled interferon-β1a (IFN- β1a) (SNG001) is being investigated as
a potential treatment for severe respiratory viral infections including COVID-19. IFN-β1a is a cytokine
that is naturally produced in the lungs, in response to viral infections. Sometimes invading viruses
switch off this mechanism, to enable viral replication allowing the virus to spread. Administering
aerosolised IFN-β1a directly into the lung airways allows for IFN-β1 levels to be restored at the site
of infection and ‘switches on’ antiviral defences. Inhaled IFN-β1a treatment is being developed as a
potential broad-spectrum variant agnostic treatment for severe viral lung infections including those
caused by SARS-CoV-2.
In this study we tested the antiviral efficacy of IFN-β1a, in vitro, against a variety of SARS-CoV-2
variants to provide reassurance that IFN-β1a was effective against the different variants as they
emerged. A 96-well micro-inhibitory, foci reduction assay with VeroE6 cells was used to determine
the amount of IFN-β1a (IU/ml) causing a 50% reduction (IC50) in viral foci compared to the virus only
control.
Results indicate that the in vitro efficacy of IFN-β1a is retained against different SARS-CoV-2 variants
including Alpha, Beta, Delta, Gamma and Omicron BA.2 variants with IC50’s ranging from 2.35 to
14.10 IU/ml.
Here we discuss the importance of continued monitoring of the efficacy of novel and
licensed treatments for COVID-19 and preparedness for future pandemics.
March 2023 Scinv’s Sprinter trial analysis. It was truly comedy gold
Scinv_temp
Posted in: SNG
Posts: 1,028
Price: 7.50
No Opinion
RE: BARDA detailed interests
31 Mar 2023 15:22
Deaths:
Day 7
Sng001 4, placebo 0
Day 14,
Sng001 9, placebo 7
Day 21
Sng001 12, placebo 9
Day 28
Sng001 14, placebo 14
Day 35
Sng001 14, placebo 17.
Total Deaths
Sng001 53, placebo 47
TommyD_19
Posts: 3,083
Price: 7.50
No Opinion
RE: BARDA detailed interests
31 Mar 2023 15:37
Scinv
14 died on drug and 17 on placebo
You’re not meant to add up each week for a grand total you muppet
Wow
The muppet who added up Sprinter trial data to get the wrong calculations for patient numbers being ventilated has returned to tell us all about the science.
When I say returned I obviously mean reusing an old account.
Https://www.synairgen.com/science/programmes
Pre-clinical research conducted by Synairgen of IFN-β (at concentrations readily achievable following inhaled delivery of SNG001) shows the inhibition of a broad range of viruses in cell-based assays including:
viruses which cause seasonal cold (e.g., RSV, Rhinovirus) and flu infections
highly pathogenic viruses such as H5N1 ‘bird flu’ and Middle East Respiratory Syndrome-Coronavirus (MERS-CoV)
Of course when it comes to directors faith, you could also say they had many opportunities after the crash when the share recovered to mid 30’s to sell shares 20 times or more above their face value but chose not to.
There are many forms of faith but probably fewer on this board amongst some.
Given the enormous possibility for ongoing trials through talks with platforms here and in the U.S. plus the interactions with parties on moving the drug forward in a partnership deal. The outcomes of trial reviews and presentations of positive results.
I wonder how many opportunities would have been available for directors to deal without contravening the regulatory guidelines on insider information
If only vaccines hadn’t been invented
If only governments hadn’t stopped funding trials
If only all drug trials were 100% guaranteed
If only we’d had 1600 patients in a trial we couldn’t afford
yadda yadda yadda
Yawn
Dundee university having referenced MX1 as a potential biomarker for severity of disease ties in nicely with out COPD findings
https://erj.ersjournals.com/content/54/suppl_63/OA263
Antiviral biomarkers are upregulated in sputum cells following administration of inhaled interferon beta to COPD patients
Sophie Reynolds, Kerry Lunn, Rona Beegan, Victoria Tear, Phillip D Monk
“Results: Inhaled IFN-β was well tolerated. All antiviral biomarkers were significantly upregulated 24hrs post dose.
Fold upregulation in Mx1 and OAS1 gene expression was similar to that seen at the same dose in stable asthmatics.
Conclusions: Antiviral biomarkers were significantly upregulated in the lungs of COPD patients following the administration of inhaled IFN-β, supporting the proposed mechanism-of-action as a treatment for virus-induced exacerbations”